Reported Friday October 11, 2024, Tevogen Bio Plans To Share $1B+ Revenue Potential Of Its Pipeline Portfolio Beginning Week Of October 14, 2024

Benzinga · 10/14 14:11

Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to share its $1B+ revenue potential, a reflection of the company's novel business approach.

 

"In the current market reality, Tevogen Bio's unique, faster, and cost-efficient drug development model has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come. With over three decades of experience in the biopharma industry, Tevogen's projected multi-billion-dollar revenue reassures me of the company's strong business fundamentals and its bold, patient-centric drug development strategy, aimed at addressing some of the most pressing health conditions impacting large patient populations," remarked Ryan Saadi, MD, MPH, Founding CEO, and 2023 Nobel Nominee.

Pipeline

  • TVGN 489:
    • Treatment of SARS-CoV-2 infection in patients with B cell hematologic cancer
    • Treatment of SARS-CoV-2 infection in patients with other cancers
    • SARS-CoV-2 infection in patients under treatment for rheumatoid arthritis
    • SARS-CoV-2 infection in patients under treatment for psoriatic arthritis
    • Treatment of Long COVID
  • TVGN 920: Cervical cancer prevention
  • TVGN 930: EBV-associated lymphomas
  • TVGN 960: Mouth and throat cancer
    • TVGN 601: Multiple sclerosis